Pediatricians and other clinical practitioners should be aware that high-dose and long-term nasal steroid administration may cause iatrogenic Cushing's syndrome characterized by complications of glucocorticoid excess as well as serious and even life-threatening complications of adrenal insufficiency.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Cushing's syndrome (CS) is common after oral steroid use and has also been reported following topical or inhaled use, but it is extremely uncommon after intranasal administration.
📊
Key Findings & Data:This is the case of a 6-year-old child who developed Cushing's syndrome after intranasal application of dexamethasone sodium phosphate for a period of 6 months.
💡
Conclusion & Impact:Pediatricians and other clinical practitioners should be aware that high-dose and long-term nasal steroid administration may cause iatrogenic Cushing's syndrome characterized by complications of glucocorticoid excess as well as serious and even life-threatening complications of adrenal insufficiency.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Cushing's syndrome (CS) is common after oral steroid use and has also been reported following topical or inhaled use, but it is extremely uncommon after intranasal administration. This is the case of a 6-year-old child who developed Cushing's syndrome after intranasal application of dexamethasone sodium phosphate for a period of 6 months. Pediatricians and other clinical practitioners should be aware that high-dose and long-term nasal steroid administration may cause iatrogenic Cushing's syndrome characterized by complications of glucocorticoid excess as well as serious and even life-threatening complications of adrenal insufficiency.
🔖
Cite This Article
DURSUN, F., KİRMİZİBEKMEZ, H. (2022). Iatrogenic Cushing's syndrome caused by intranasal steroid use. İstanbul Kuzey Klinikleri, Cilt: 4 - Sayı: 1, 97–99. https://ajindex.com/articles/551572
Baş VN, Cetinkaya S, Aycan Z. Iatrogenic Cushing syndrome due to nasal steroid drops. Eur J Pediatr 2012;171:735–6
Dutta D, Shivaprasad KS, Ghosh S, Mukhopadhyay S, Chowdhury S. Iatrogenic Cushing’s syndrome following short-term intranasal steroid use. J Clin Res Pediatr Endocrinol 2012;4:157– 9
Mahlab-Guri K, Asher I, Gradstein S, Zung A, Radian-Sade S, Elbirt D, et al. Inhaled fluticasone causes iatrogenic cushing’s syndrome in patients treated with Ritonavir. J Asthma 2011;48:860–3
Fuchs M, Wetzig H, Kertscher F, Täschner R, Keller E. Iatrogenic Cushing syndrome and mutatio tarda caused by dexamethasone containing nose drops. [Article in German] HNO 1999;47:647–50. [Abstract] 5. Oluwayemi IO, Oduwole AO, Oyenusi E, Onyiriuka AN, Abdullahi M, Fakeye-Udeogu OB, et al. Iatrogenic Cushing’s syndrome in children following nasal steroid. Pan Afr Med J 2014;17:237
Perry RJ, Findlay CA, Donaldson MD. Cushing’s syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. Arch Dis Child 2002;87:45–8
Kimmerle R, Rolla AR. Iatrogenic Cushing’s syndrome due to dexamethasone nasal drops. Am J Med 1985;79:535–7
Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991;72:39–45
Wilkins W, Thomas CC, Springfield, Ill. The diagnosis and treatment of Endocrine. Disorders in childhood 1950.